Citi lowered the firm’s price target on Cabaletta Bio (CABA) to $13 from $17 and keeps a Buy rating on the shares post the Q1 report. The company has received FDA alignment on a registrational trial design for rese-cel in myositis and now anticipates application submission for full approval in 2027, the analyst tells investors in a research note. With regulatory alignment in hand, Citi thinks Cabaletta is leading in the myositis CAR-T space and could be first to launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio’s Strong Financial Position and Strategic Clinical Progress Justify Buy Rating
- Cabaletta Bio price target raised to $25 from $23 at Guggenheim
- Cabaletta Bio Announces 2027 BLA Plans for Rese-cel
- Cabaletta Bio announces plans for anticipated 2027 rese-cel BLA submission
- Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases